Biocardia Inc (BCDA)

$2.69

-0.05

(-1.82%)▲

Market is closed - opens 7 PM, 08 Oct 2024

Performance

  • $2.60
    $2.73
    $2.69
    downward going graph

    3.35%

    Downside

    Day's Volatility :4.76%

    Upside

    1.47%

    downward going graph
  • $1.96
    $23.25
    $2.69
    downward going graph

    27.28%

    Downside

    52 Weeks Volatility :91.59%

    Upside

    88.43%

    downward going graph

Returns

PeriodBiocardia IncIndex (Russel 2000)
3 Months
-5.84%
0.0%
6 Months
-52.9%
0.0%
1 Year
-51.47%
0.0%
3 Years
-93.85%
-21.4%

Highlights

Market Capitalization
9.6M
Book Value
- $0.92
Earnings Per Share (EPS)
-5.33
PEG Ratio
0.0
Wall Street Target Price
25.0
Profit Margin
0.0%
Operating Margin TTM
-54966.67%
Return On Assets TTM
-115.93%
Return On Equity TTM
-703.62%
Revenue TTM
428.0K
Revenue Per Share TTM
0.26
Quarterly Revenue Growth YOY
-93.0%
Gross Profit TTM
-7.5M
EBITDA
-8.5M
Diluted Eps TTM
-5.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.06
EPS Estimate Next Year
-1.27
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Biocardia Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 829.37%

Current $2.69
Target $25.00

Company Financials

FY18Y/Y Change
Revenue
625.0K
↑ 30.48%
Net Income
-13.9M
↑ 12.71%
Net Profit Margin
-2.2K%
↑ 350.0%
FY19Y/Y Change
Revenue
710.0K
↑ 13.6%
Net Income
-14.8M
↑ 6.83%
Net Profit Margin
-2.1K%
↑ 132.34%
FY20Y/Y Change
Revenue
145.0K
↓ 79.58%
Net Income
-15.0M
↑ 1.26%
Net Profit Margin
-10.3K%
↓ 8261.1%
FY21Y/Y Change
Revenue
1.0M
↑ 600.0%
Net Income
-12.6M
↓ 15.89%
Net Profit Margin
-1.2K%
↑ 9104.83%
FY22Y/Y Change
Revenue
1.4M
↑ 33.2%
Net Income
-11.9M
↓ 5.61%
Net Profit Margin
-881.14%
↑ 362.31%
FY23Y/Y Change
Revenue
477.0K
↓ 64.72%
Net Income
-11.6M
↓ 2.87%
Net Profit Margin
-2.4K%
↓ 1544.65%
Q1 FY23Q/Q Change
Revenue
64.0K
↓ 39.62%
Net Income
-3.5M
↑ 14.94%
Net Profit Margin
-5.5K%
↓ 2590.21%
Q2 FY23Q/Q Change
Revenue
43.0K
↓ 32.81%
Net Income
-3.4M
↓ 1.95%
Net Profit Margin
-8.0K%
↓ 2506.54%
Q3 FY23Q/Q Change
Revenue
357.0K
↑ 730.23%
Net Income
-2.6M
↓ 24.82%
Net Profit Margin
-721.01%
↑ 7241.78%
Q4 FY23Q/Q Change
Revenue
13.0K
↓ 96.36%
Net Income
-2.1M
↓ 19.5%
Net Profit Margin
-15.9K%
↓ 15217.45%
Q1 FY24Q/Q Change
Revenue
55.0K
↑ 323.08%
Net Income
-2.3M
↑ 9.41%
Net Profit Margin
-4.1K%
↑ 11816.64%
Q2 FY24Q/Q Change
Revenue
3.0K
↓ 94.55%
Net Income
-1.6M
↓ 27.39%
Net Profit Margin
-54.9K%
↓ 50744.85%
FY18Y/Y Change
Total Assets
6.4M
↓ 52.6%
Total Liabilities
2.6M
↑ 8.79%
FY19Y/Y Change
Total Assets
7.7M
↑ 19.65%
Total Liabilities
5.3M
↑ 102.21%
FY20Y/Y Change
Total Assets
23.4M
↑ 205.08%
Total Liabilities
4.2M
↓ 19.97%
FY21Y/Y Change
Total Assets
15.7M
↓ 32.9%
Total Liabilities
5.3M
↑ 25.78%
FY22Y/Y Change
Total Assets
9.8M
↓ 37.7%
Total Liabilities
4.9M
↓ 8.27%
FY23Y/Y Change
Total Assets
3.0M
↓ 69.5%
Total Liabilities
4.6M
↓ 6.35%
Q1 FY23Q/Q Change
Total Assets
7.1M
↓ 27.21%
Total Liabilities
5.2M
↑ 6.67%
Q2 FY23Q/Q Change
Total Assets
6.4M
↓ 10.37%
Total Liabilities
4.8M
↓ 9.07%
Q3 FY23Q/Q Change
Total Assets
3.7M
↓ 41.35%
Total Liabilities
4.4M
↓ 7.3%
Q4 FY23Q/Q Change
Total Assets
3.0M
↓ 20.28%
Total Liabilities
4.6M
↑ 4.15%
Q1 FY24Q/Q Change
Total Assets
2.7M
↓ 10.31%
Total Liabilities
5.0M
↑ 7.93%
Q2 FY24Q/Q Change
Total Assets
2.9M
↑ 7.88%
Total Liabilities
4.9M
↓ 2.08%
FY18Y/Y Change
Operating Cash Flow
-11.1M
↑ 27.66%
Investing Cash Flow
-66.0K
↓ 51.47%
Financing Cash Flow
3.8M
↑ 2541.67%
FY19Y/Y Change
Operating Cash Flow
-9.4M
↓ 14.67%
Investing Cash Flow
-146.0K
↑ 121.21%
Financing Cash Flow
9.8M
↑ 158.1%
FY20Y/Y Change
Operating Cash Flow
-12.4M
↑ 30.83%
Investing Cash Flow
-32.0K
↓ 78.08%
Financing Cash Flow
28.2M
↑ 187.34%
FY21Y/Y Change
Operating Cash Flow
-10.4M
↓ 16.11%
Investing Cash Flow
-116.0K
↑ 262.5%
Financing Cash Flow
1.9M
↓ 93.1%
FY22Y/Y Change
Operating Cash Flow
-10.6M
↑ 1.88%
Investing Cash Flow
-70.0K
↓ 39.66%
Financing Cash Flow
5.1M
↑ 163.07%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 14.58%
Investing Cash Flow
-10.0K
↑ 400.0%
Financing Cash Flow
64.0K
↓ 98.27%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.2M
↑ 23.09%
Investing Cash Flow
-2.0K
↓ 80.0%
Financing Cash Flow
2.6M
↑ 3964.06%

Technicals Summary

Sell

Neutral

Buy

Biocardia Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biocardia Inc
Biocardia Inc
13.69%
-52.9%
-51.47%
-93.85%
-94.29%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.53%
7.92%
21.76%
83.48%
256.87%
Novo Nordisk A/s
Novo Nordisk A/s
-12.73%
-9.68%
25.05%
134.03%
343.37%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.86%
71.74%
59.21%
32.07%
248.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.35%
12.64%
28.18%
152.92%
164.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biocardia Inc
Biocardia Inc
NA
NA
0.0
-5.06
-7.04
-1.16
NA
-0.92
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biocardia Inc
Biocardia Inc
Buy
$9.6M
-94.29%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
256.87%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
343.37%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.4B
248.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
164.64%
32.84
-4.74%

Insights on Biocardia Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 55.0K → 3.0K (in $), with an average decrease of 94.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -2.26M → -1.64M (in $), with an average increase of 37.7% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 105.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 125.9%

Institutional Holdings

  • Susquehanna International Group, LLP

    1.27%

  • Geode Capital Management, LLC

    0.37%

  • Vanguard Group Inc

    0.37%

  • Tower Research Capital LLC

    0.09%

  • Advisor Group Holdings, Inc.

    0.04%

  • Pingora Partners LLC

    0.03%

Company Information

we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Organization
Biocardia Inc
Employees
16
CEO
Dr. Peter A. Altman Ph.D.
Industry
Biotechnology

Discover More

FAQs